DTRMWXHS-12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: An open-label, multicenter, phase 1a/1b study

Results from the first in human phase 1a/1b study of novel BTK inhibitor DTRMWXHS-12 in combination with everolimus and pomalidomide in patients with relpased/refractory lymphomas (including both CLL and Richter's Transformation) found a maximum tolerated dose (MTD) of 200 mg DTRMWXHS-12 + 5 mg of everolimus + 2 mg of pomalidomide. This combination is based on preclinical studies that demonstrate augmented activity when BTK inhibitors are given with mTOR and IMiD inhibitors. Across all cohorts, which included both CLL and Richter's Transformation, responses were seen in 41.9% of patients, and tolerability of this all oral comibination therapy regimen was established. Additional safety and efficacy data will be forthcoming.